Cencora, Inc. (COR) Q4 2025 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

The earnings call highlights strong financial performance with a 9% revenue growth and 16% operating income increase. The raised EPS guidance and strategic focus on specialty growth and MSO platforms are positive indicators. The Q&A session reveals confidence in sustainable growth and strategic investments, despite some uncertainties in asset sales. The dividend increase and share repurchases further enhance shareholder value. Overall, the company's optimistic outlook, strategic execution, and financial metrics suggest a positive stock price movement over the next two weeks.

Key Financial Performance

Adjusted Operating Income and Adjusted Diluted EPS Growth of 16% year-over-year, driven by strategic positioning in Specialty, investments in fast-growing areas, and strong pharmaceutical utilization trends.

Adjusted Diluted EPS (Q4) $3.84, an increase of 15% year-over-year, driven by strong performance in the U.S. Healthcare Solutions segment.

Consolidated Revenue (Q4) $83.7 billion, up 6% year-over-year, primarily due to continued volume growth in both reportable segments.

Consolidated Gross Profit (Q4) $2.9 billion, up 18% year-over-year, driven by gross profit growth in the U.S. Healthcare Solutions segment and the acquisition of Retina Consultants of America.

Consolidated Operating Income (Q4) $1 billion, up 20% year-over-year, driven by strong growth in the U.S. Healthcare Solutions segment.

Net Interest Expense (Q4) $78 million, an increase of $57 million year-over-year, primarily due to $3.3 billion in debt raised for the RCA acquisition.

Effective Tax Rate (Q4) 20.6%, compared to 20.3% in the prior year quarter.

U.S. Healthcare Solutions Segment Revenue (Q4) $75.8 billion, up 6% year-over-year, driven by strong utilization trends and a 10% increase in sales of GLP-1 products.

U.S. Healthcare Solutions Segment Operating Income (Q4) $872 million, up 25% year-over-year, driven by growth across distribution businesses and the contribution from RCA.

International Healthcare Solutions Segment Revenue (Q4) $7.9 billion, up 8% year-over-year (6% on a constant currency basis), driven by growth in the European distribution business.

International Healthcare Solutions Segment Operating Income (Q4) $151 million, a 2% decrease year-over-year (6% decrease on a constant currency basis), due to pressure in global consulting services businesses.

Consolidated Revenue (Full Year Fiscal 2025) $321.3 billion, up 9% year-over-year, driven by 10% growth in U.S. Healthcare Solutions and 6% growth in International Healthcare Solutions.

Consolidated Operating Income (Full Year Fiscal 2025) $4.2 billion, up 16% year-over-year, driven by volume growth in specialty and contribution from the RCA acquisition.

Adjusted Free Cash Flow (Full Year Fiscal 2025) $3 billion, with a cash balance of $4.4 billion at year-end.

Dividends and Share Repurchases (Full Year Fiscal 2025) Close to $900 million returned to shareholders, including a 9% increase in the quarterly dividend.

You have reached the limit Upgrade to access full content

Get started

Operating Highlights

Acquisition of Retina Consultants of America (RCA): Cencora acquired RCA to strengthen its leadership in specialty healthcare. The acquisition has demonstrated value for physicians and enhanced patient outcomes through innovative treatments and research capabilities.

Investments in distribution network: Cencora announced $1 billion in investments through 2030 to expand its distribution network, including a second National Distribution Center and increased specialty distribution capacity.

Expansion in European distribution: The International Healthcare Solutions segment saw revenue growth driven by strong demand for 3PL services and new contracts in Europe.

Portfolio review and strategic alternatives: Cencora is evaluating strategic alternatives for non-core businesses, including MWI Animal Health, Profarma in Brazil, and certain components of PharmaLex, to focus on growth-oriented investments.

Enhanced supply chain infrastructure: Investments in supply chain infrastructure aim to improve efficiency and support rising demand for pharmaceutical treatments.

Focus on specialty healthcare: Cencora is prioritizing specialty healthcare as a core growth area, supported by acquisitions and internal investments.

Simplification of PharmaLex: PharmaLex will now focus on pharmacovigilance, market access, and regulatory affairs, with other service verticals under evaluation for strategic alternatives.

You have reached the limit Upgrade to access full content

Get started

Risk or Challenges

Strategic Portfolio Realignment: Cencora is evaluating strategic alternatives for certain businesses, including MWI Animal Health, legacy U.S. hub services, equity investment in Profarma, and components of PharmaLex. This could lead to operational disruptions or challenges in finding suitable partners.

PharmaLex Performance: PharmaLex has experienced persistent demand challenges, resulting in a $724 million goodwill impairment. Simplifying its business and focusing on specific areas may not fully address its underperformance.

Debt and Interest Expense: The $3.3 billion debt raised for the RCA acquisition has increased interest expenses significantly, posing financial strain. Although $700 million has been repaid, the remaining debt could impact financial flexibility.

Oncology Customer Loss: The loss of an oncology customer due to its acquisition by a peer will create a headwind for the first three quarters of fiscal 2026, impacting revenue and operating income growth.

International Healthcare Solutions Segment: Operating income in this segment decreased by 2% due to pressure in global consulting services, which could continue to affect profitability.

Supply Chain Investments: Significant investments of $1 billion through 2030 in supply chain infrastructure may strain resources and require careful execution to ensure ROI.

Regulatory and Market Risks: Forward-looking statements are subject to regulatory and market uncertainties, which could impact financial and operational performance.

You have reached the limit Upgrade to access full content

Get started

Guidance & Outlook

Adjusted Operating Income Growth: Cencora has raised its long-term guidance for adjusted operating income growth to a range of 6% to 9%, up from the previous range of 5% to 8%.

Adjusted EPS Growth: The company has increased its long-term guidance for adjusted EPS growth to a range of 9% to 13%.

Fiscal 2026 Adjusted EPS: Expected to be in the range of $17.45 to $17.75, representing growth of 9% to 11%.

Fiscal 2026 Revenue Growth: Consolidated revenue growth is expected to be in the range of 5% to 7%, with U.S. Healthcare Solutions revenue growth of 5% to 7%, International Healthcare Solutions revenue growth of 6% to 8%, and 'other' revenue growth of 0% to 4%.

Fiscal 2026 Operating Income Growth: Consolidated operating income growth is expected to be in the range of 8% to 10%, with U.S. Healthcare Solutions operating income growth of 9% to 11%, International Healthcare Solutions operating income growth of 5% to 8%, and 'other' operating income decline of 1% to 4%.

Capital Expenditures: Cencora plans to invest approximately $900 million in fiscal 2026, including significant investments in U.S. supply chain infrastructure and IT to support digital transformation.

Free Cash Flow: Adjusted free cash flow is expected to be approximately $3 billion for fiscal 2026.

Dividend Growth: The Board of Directors approved a 9% increase in the quarterly dividend, aligning with the low end of the long-term adjusted EPS growth guidance.

Long-Term EPS Growth: Cencora expects long-term EPS growth in the range of 9% to 13%, driven by operating income growth and contributions from M&A and share repurchases.

Specialty Market Investments: Cencora announced $1 billion in investments through 2030 to expand its distribution network, including a second National Distribution Center and enhanced specialty distribution capacity.

You have reached the limit Upgrade to access full content

Get started

Shareholder Return Plan

Annual Dividend Increase: The Board of Directors approved a 9% increase to the quarterly dividend, marking the twenty-first consecutive annual dividend increase. This aligns the dividend growth rate to the low end of the long-term guidance for adjusted diluted EPS growth.

Share Repurchase: Cencora prioritized returning capital to shareholders through share repurchases totaling close to $900 million during fiscal 2025. Additionally, the company plans approximately $1 billion in share repurchases over the course of fiscal 2026.

You have reached the limit Upgrade to access full content

Get started

Key Q&A

Q:Can you maybe just spend a minute strategically how you view the business?

A:The company is focused on strategic execution, dedicating resources and capital to areas that align with their strategy. They are investing in MSO platforms like RCA and OneOncology to make care easier for patients and physicians, and are focused on specialty growth areas.

Q:What are the next steps in the evolution of the MSO platform?

A:The next steps involve leveraging capabilities across MSO platforms, such as clinical trial expertise and back-office activities like revenue cycle management. These efforts aim to enhance care for physicians and patients and improve operational efficiency.

Q:What is driving the level of magnitude of growth in the U.S. AOI performance, and how durable are these drivers?

A:The U.S. segment saw 25% adjusted operating income growth in Q4, driven by strong performance in RCA and OneOncology. Excluding RCA, growth was 13%, despite headwinds from COVID and the loss of an oncology customer. The company expects continued strong performance but at a moderated level in FY '26.

Q:Is the core growth above the long-range plan (LRP) at the moment, and does the capital deployment already contemplate the next step in the OneOncology transaction?

A:The core growth is strong, and the LRP reflects potential future events like customer acquisitions. The capital deployment priorities include the OneOncology transaction, which is already embedded in the long-term guidance.

Q:Can you talk about the overlap with your core business across some of those other businesses that are now in the 'other' segment?

A:MWI and other businesses in the 'other' segment do not provide a competitive advantage to the core enterprise. Exploring strategic alternatives aims to better position these businesses for long-term success. Core businesses like World Courier and Alliance Healthcare remain focused on specialty growth.

Q:Should we think about the relative growth rate between specialty and generics in the U.S. healthcare segment?

A:Specialty growth is accretive to operating income growth, driven by innovation and investments in MSO strategy. Generic deflation has moderated, and all parts of the business, including brand, specialty, and generic, contribute positively.

Q:What is enabling the pivot to 5% to 8% growth in the international business in FY '26?

A:The pivot is driven by a rebound in global specialty logistics (e.g., World Courier) and strong performance in core businesses like Alliance Healthcare's 3PL services. Easier comparisons and a more tailored portfolio also contribute to the growth.

Q:Should we think about potential accretion or dilution related to asset sales in the 'other' segment?

A:Asset sales could be dilutive in the short term but are expected to drive better long-term returns and accretion by focusing on higher-growth businesses. All businesses in the 'other' segment are currently profitable.

Q:Has the business inflected to a point where margin expansion is sustainable on an ongoing basis?

A:The business benefits from specialty services and MSO strategy, which are accretive to margins. While margins are important, the company also focuses on return on invested capital. The specialty market and balanced portfolio contribute to sustainable growth.

Q:What has driven the upside in the macro and the ability to raise guidance?

A:The upside is not due to macro changes but rather the company's historical results, strong specialty market growth, and strategic investments. The company has been positioning itself for this moment through careful planning and execution.

Q:How are capital deployment priorities informing near-term M&A strategy, and when is the OneOncology call option expected to be exercised?

A:Capital deployment focuses on internal investments, strategic M&A, share repurchases, and dividends. The OneOncology call option is expected to be exercised, and the company is pleased with its growth and contributions to specialty sales.

Q:Review of Unclear Management Responses

A:Management avoided directly addressing the specific timing of the OneOncology call option exercise and provided limited details on the exact financial impact of potential asset sales in the 'other' segment.

You have reached the limit Upgrade to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

COR Transcript

Cencora, Inc. (COR) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Neutral12-2

Cencora, Inc. (COR) Presents at Evercore 8th Annual Healthcare Conference Transcript

Neutral12-2

Cencora, Inc. (COR) Q4 2025 Earnings Call Transcript

Positive11-5

Cencora, Inc. (COR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Neutral9-10

COR Slides

Cencora Q2 2025 slides: adjusted EPS jumps 16.3%, guidance raised

2025-05-07

Cencora Q3 2025 slides: U.S. segment drives 19.8% EPS growth, guidance raised

2025-08-06

COR Report

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.